FDA's September announcement that it plans to transfer some therapeutic biologic review functions from the Center for Biologics Evaluation and Research (CBER) to the Center for Drug Evaluation and ...
FDA’s Office of New Drugs restricting aims to improve scientific exchange and information sharing among review professionals. The Office of New Drugs (OND) in FDA’s Center for Drug Evaluation (CDER) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback